on the HUNT for the Next DIAMOND in the ROUGH
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
to the moon
Especially with all their patents
Easily should be a market cap. pf 30 Mil.
now only at a mil.
WAY WAY undervalued
AMBS bought By AMGEN Co-Founder(LARGEST Indep. BIOTECH)
Amgen is the world's largest independent biotechnology firm. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.
still at looow levels
This is going to be the play of the year!
AMBS bought By AMGEN
Amgen is the world's largest independent biotechnology firm. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.
still at looow levels
This is going to be the play of the year!
IMO
AMGEN buys into AMBS
Next Partner?
They are a large Biotech Co.
Amgen is the world's largest independent biotechnology firm. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.
MANF to BE THE NEXT ONE
Why for any other reason than to an agreement soon to be released would they invest in AMBS
HUUUUUUUUUGE GAINs ON this One !
IMO
It may be closed longer....this is a storm for the history books....I may be out of power for 7 to 10 days the whole city could be totally crippled with water damage! Hoping for the best though
AMBS for the record books!
Thank you....I'm 20 miles east of NYC on Long Island...she's a comin
Hopefully the Market is open tomorrow- This is an Unprecedented Storm
The Water rising 6 to 12 ft. over normal levels will do the most damage
Everyone have a wonderful day!
Amarantus Appoints Clinton Allen(Bristol Myers Exec.) To Advisory Board
Print
Alert
Amarantus Biosci (OTCBB:AMBS)
Historical Stock Chart
1 Month : From Sep 2012 to Oct 2012
Click Here for more Amarantus Biosci Charts.
SUNNYVALE, Calif., Oct. 19, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Clinton O. Allen to its Advisory Board. Mr. Allen will work with management at Amarantus to improve internal controls, prepare due diligence materials for investors and implement corporate governance best practices.
"Clinton Allen is a seasoned biopharmaceutical executive with exceptional leadership capabilities and experience in Big Pharma," said Gerald E. Commissiong, President & CEO of Amarantus. "He will be a tremendous asset for the Company as we execute on our corporate strategy."
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development.[/b] Mr. Allen was a captain in the United States Army and received his master in Environmental Management & Sciences from Tufts University.
"I am very excited to join Amarantus at this critical time in its growth cycle," said Clinton O. Allen, newly appointed advisor to Amarantus. "The team at Amarantus has been working tremendously hard over the last few years to bring the MANF Program closer to actualizing its true potential. Now that the Company is looking at various partnering and funding opportunities to drive shareholder value, it is an opportune time to join the team in order meticulously evaluate proposals and make recommendations for future growth."
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
MEDIA CONTACTS
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408-737-2734
pr@amarantus.com
SOURCE Amarantus BioSciences, Inc.
Copyright 2012 PR Newswire
Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parki...
Amarantus Biosci (OTCBB:AMBS)
Historical Stock Chart
1 Month : From Sep 2012 to Oct 2012
Click Here for more Amarantus Biosci Charts.
SUNNYVALE, Calif., Oct. 25, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
In Parkinson's disease, the nigro-striatal network (substantia nigra – striatum) is compromised due to the degeneration of dopaminergic neurons in the substantia nigra, which results in dopaminergic nerve terminal retraction from the striatum towards the substantia nigra. This leaves the striatum with inadequate dopamine levels, which in turn causes motor function deficits and other symptoms. Currently approved drugs that relieve symptoms focus on replacing the dopamine lost in the striatum; however, the symptom relief is temporary and the drugs typically lose their ability to abate symptoms roughly 7-10 years after the initiation of drug therapy. There are no approved therapies that focus on re-innervating the striatum by protecting dopaminergic neuron cell bodies in the substantia nigra while restoring dopaminergic innervation in the striatum.
In rat studies conducted by an independent academic laboratory contracted by Amarantus, 6-OHDA was injected directly into the striatum on one side of each rat's brain, causing their dopaminergic terminals to retract from the striatum towards the substantia nigra, and creating Parkinson's-like behavioural symptoms that were quantified by counting the number of times the rats turned in a circle in the same direction (behavioural deficits) in a given 120 minute period of time. MANF and GDNF were delivered directly into the substantia nigra of separate groups of rats 2 weeks following the administration of the 6-OHDA, in order to mimic as closely as possible in rats the treatment setting in humans where treatment would be administered after an extended timeframe following the initiation of dopaminergic nerve terminal retraction, each at the optimal dosing level of 10 micrograms. Four weeks following MANF treatment into the substantia nigra, behavioural deficits were reduced by ~43%, and six weeks following MANF treatment, behavioural deficits were reduced by ~53%; four weeks following GDNF treatment into the substantia nigra, behavioural deficits were reduced by ~16%, and six weeks following GDNF treatment, behavioural deficits actually increased by ~20%.
"The data obtained in this study provide clear evidence that MANF had a strong positive and restorative effect on the behaviour of animals in this pre-clinical Parkinson's disease study when delivered to the substantia nigra, whereas GDNF had no such effect," said John W. Commissiong PhD, Chief Scientist at Amarantus and former Head of the Neurotrophic Factors Group at the National Institutes of Health. "The localization of the drug treatment in this study is critical because, as Parkinson's disease progresses, dopaminergic nerve terminals typically retract from the striatum towards their cell bodies in the substantia nigra, resulting in the disruption of the basal ganglia network that is responsible for proper motor function. Translated, the longer you have Parkinson's disease, the less likely a neurotrophic factor will work when delivered to the striatum because there are fewer dopaminergic nerve terminals remaining to act on, and so neurotrophic factor drugs for later-stage patients will likely work best when delivered to the substantia nigra. No neurotrophic factor other than MANF has demonstrated efficacy in the neurorestoration behavioural 6-OHDA model of Parkinson's disease when delivered to the substantia nigra, so this makes today's result very significant. We are currently working to complete the analysis of histology data to confirm that it is in fact dopaminergic re-innervation of the striatum that is responsible for the results reported today. We expect to release the final results, including histology, to the public when the final data package is assembled in the next few months, and we will submit the final study report and manuscript for publication to a peer-reviewed scientific journal jointly with our academic collaborators and study sponsors at the same time. If the histology data confirm the mechanism underlying the behavioural results reported today, the biology [i]causing today's result would represent a major scientific achievement that could lead to a medical breakthrough in treating Parkinson's disease."
Neurotrophic factors have been promising drug candidates for Parkinson's disease for over two decades because they have special biological properties that allow them to selectively protect certain neurons. Large biotechnology companies and leading academic investigators have conducted a number of clinical trials on GDNF in Parkinson's disease first initiated in 1996, at an estimated total cost of over $400M, where GDNF has shown promise as a disease-modifying treatment. However, technological limitations of delivering neurotrophic factors to the brain, limitations that Amarantus believes have been resolved by researchers in academia and industry, have delayed the translation of the underlying biology of neurotrophic factors into approved medicines. A unique drug such as MANF that potentially acts by re-innervating the striatum when delivered to the substantia nigra, combined with newly improved delivery technologies capable of getting MANF to the substantia nigra, could complement or replace drugs in development that may get to market ahead of MANF, especially in later-stage patients.
"Today's announcement is transformational for Amarantus from a scientific data standpoint," said Gerald E. Commissiong, President & CEO of Amarantus. "Despite the many clear scientific advantages we believe MANF possesses over GDNF, most notably impacting protein folding and modulating toxic calcium levels, the Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson's disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents. We believe that we are well positioned to leverage the MANF opportunity for Amarantus shareholders and Parkinson's patients because of the expansive intellectual property (IP) portfolio the Company owns, including composition of matter patents in the US and Europe, use patents worldwide and provisional delivery dosing patents that have been filed based on today's data, extending marketing exclusivity for MANF through 2031. This IP position may make MANF more attractive to a potential partner than other neurotrophic factors in development that do not have the same patent runway."
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
MEDIA CONTACTS
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408-737-2734
pr@amarantus.com
SOURCE Amarantus BioSciences, Inc.
Copyright 2012 PR Newswire
I do believe this will move fast now that people believe in the new Pres. and that it is not a scam
$AMBS We already have a former director of Bristol Myers (a 55 billion dollar biotech Co.) on board so this should be all work out the way I like it
$AMBS fast forward to 4:13 to listen about what the Company's plans are with their IP(intellectual portfolio) one of them being Manf
I would hold on.....most likely Amarantus will partner with a large Biotech which will benefit us all substantially and then that is only the tip of the iceberg.....They have No intentions on bringing this through FDA approval on their own --but just the rights to the molecular protein is worth 30 million plus ( and that's being conservative)That should put our PPS from .10 to .30!
The news could come out at any time also of a Letter of Intent
http://ih.advfn.com/videos/stock-research/amarantus-biosciences-interviewed-on-the-big-biz-radio-show_nseWcV4uvO8
They own rights to a Protein which reverses CELL DEATH. This Protein (MANF) has Many Many other uses for other diseases in the future but they first started with Parkinson's most Likely b/c of the Michael j. Fox Foundation Funding them in the beginning.
http://adage.com/article/agency-news/agencies-plan-survive-pharmageddon/237031/
As Drugs Fall Off Patent Cliff, Agencies Are Rethinking Health Care With New Practices, Approaches
By: Alexandra Bruell Published: September 10, 2012
I don't feel the same....Co. is in the market for a BIG BIO Co. to Take Over the rest of the Fda approval process/expenses
with this last pr that will open the eyes of many of them and then its.....to the highest bidder but remember they have many different uses for MANF (that stops cell death)
So they could partner up for the use of Parkinson's then another for heart disease and so on
The videos explain the intentions of the co. much more thoroughly
THIS IS HUGE
FOR anyone just here just playing the charts...I would hope you would take the time to watch the videos.....Very Exciting
Dept of Defense involved for TBI
Be on the Show
Be on the Show? Pitch It to Producer Mo:
“The Big Biz Show with Sully and Russ T. Nailz,” nationally syndicated radio/tv program broadcast on 150 am stations across the country, internet sites via BTRN, CBS Radio, Chat-About-It, Yahoo Radio, AOL Radio and wsRadio.com and airing on WealthTV Network nationwide.
Would need guest to call 866.606.8255 @ designated date/time and identify him/herself as next guest for live radio interview. Will need guest bio/brief on company/book and topic and talking points for live radio interview show prep.
Scheduled radio interviews are @ 1:10/1:40/2:10/2:40pm Pacific Standard Time Monday-Friday.
“The Big Biz Show” with Russ and Sully has been featured on Fox Business Network with Stuart Varney and Dagen McDowell. They are extrememly talented, funny, irreverent and optimistic with great “take away” financial advice. Both Sully and Russ have over 20 years experience in broadcast media. In addition to The Big Biz Show, Sully is a rotating “fill in” host for nationally syndicated Roger Hedgecock and Russ is a stand up comic, motivational speaker and charity auctioneer! Russ and Sully have an energy and dynamic unmatched in media today.
I'm waiting for CEO to be on it for a fifth time with this last pr to get some Big Investors ON-BOARD
Check out the names below who have been guests!
If you are wondering.....its a couple of videos on the right of the screen
"The Big Biz Show" named in the TOP TEN Financial Radio Talk Shows by TALKERS Magazine
Sully is a San Diego Radio/TV Personality who has something to say about all things in the World of Business!
Monday - Friday 9am - 12pm PT / 12pm - 3pm ET.
Sully covers current events, business trends, investment opportunities, innovations in headline making industries, hot stock picks, live market updates, interviews of global movers, shakers and entrepreneurs, weekly features, a daily dose of common sense and good old fashioned humor. Sully DELIVERS!
Sully is the "Money Guy" and has a unique energy unmatched in the Radio/TV industry today. If it relates to business, Sully is talking about it - with his laid back, irreverent, comic - often hilarious - always informative, packed with valuable'take away' commentary of goings on in the business world and investment arena.
"Business Talk with a bar room flair..." Wall Street Journal
Sully gets down to business and leave listeners wanting more! And it's never a dull moment with Big Biz Show Cast regulars...
Intriguing, enlightening National Guests featured daily, including...
Steve Forbes
Ted Nugent
Rita Rudner
Jesse Ventura
Newt Gingrich
Gary Sinise
Lis Weihl
Dennis Green
You'll never know who will join the Cast on "The Big Biz Show"
"The Big Biz Show" - It's NOT your "Father's Business Talk Show" - It's Business Talk for the rest of us!
apology accepted....now lets make $$
Why would I respond to being an idiot?
and I am holdin much much more shres than that.....maybe too many for a penny but I feel Very Confident about this Company.
Maybe I should take my own advice that hogs get slaughtered..lol
i was talking about my L2 streamer.....
I have NOT sold 1 of my shares.... maybe it would be safer to start unloading but I have done hrs. and hrs of research on this co. and it only looks better and better every day I dig deeper and more news comes out and more eyes come looking-
GLTU DOC
I guess I wasn't clear....I was just giving an example ...MANF is has proven itself to be SUPERIOR to a product which large biotech Co's have spent 400 million on
Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson's disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents
I don't even think you understand what this co. is about and what it has a patent on and so on and so forth.
The Dilution is over otherwise the million share sitting on the bid would have been filled
Have A great Weekend
I wouldn't worry ...those million shares sitting at the bid will have to move to the ask if no-one gets impatient especially because the news has been getting better and better and we will most likely see some more on Monday. but I also have only 55,000 sold @ .006 the rest @ .0067
$AMBS former executive of BRISTOL MYERS on BOARD
This is going to be very interesting....they have a patent on a medical breakthrough which is just getting out
Any Guesses to where the price will go When We Announce a MAJOR BIOTECH CO. as a Partner
Easily 1000% Gains from Here in Near term
$AMBS
IMO
I do believe all the .005's sold in the past couple weeks are in wise hands.
This is going to be on top of Most READ BOARDS in the very Near future
You should be grateful you are here on the ground floor....I know I am
Does anyone here actually realize what the company has accomplished.....yesterdays news is Very Significant.
Can someone tell me why it is significant.....
Why would someone take 1 hr. energy drink when we have a patent on a 5 hr. energy drink...The 1 hr. energy drink took other co.'s over 400 MILLION Dollars to develop but WE have something Much BETTER
HERE come the BIG PHARMACEUTICAL COMPANIES as PARTNERS knocking on our door.
I wouldn't want to be caught with my pockets empty when this news hits
$AMBS
senior vice president for Research at Bristol-Myers Squibb. "As part of our strategy, we continually seek to build relationships with organizations that have innovative programs and capabilities that complement our own internal efforts.
http://www.news-medical.net/news/20120921/Vanderbilt-Bristol-Myers-Squibb-partner-to-advance-Parkinsone28099s-disease-treatment.aspx?page=2
Bristol-Myers Squibb $AMBS potential partners
they recently appointed former senior leader of Bristol
They have the patent on a protein Bristol could capitalize on
It is possible
All you need is one Breakthrough and they all will line up with their hands out
I think we have a Patent on the Breakthrough in biotechs
THAT would be a VERY NICE PARTNER
They already have someone who knows many who Lead there and make decisions
Research from ONEMEDPLACE about AMARANTUS last month
http://www.onemedplace.com/reports/Amarantus_Research_Analysis.pdf
Amarantus' license for NuroPro, our clinical-stage Parkinson's disease diagnostic blood test, has several potential positive benefits for our MANF Parkinson's program including the identification of patients most likely to respond to MANF treatment. We intend to immediately pursue a partnering strategy for NuroPro and expect to update the marketplace once definitive agreements are reached. NuroPro could become a significant source of revenue for the Company within a relatively short period of time and its further development could have a major impact on the way Parkinson's disease is diagnosed and managed by physicians.
As we further carve-out our position as the partner of choice for any MANF-based product development effort, we expect that we will be successful in attracting the necessary financial commitments to move MANF into clinical testing based upon the success of experiments already underway. As we continue to show progress in Parkinson's disease, we will likely be in a good negotiating position with potential partners seeking to commercialize MANF both in Parkinson's and other medical conditions, which could create multiple partnering opportunities for the Company.
As new and exciting proof-of-concept data for MANF in secondary therapeutic indications continues to be published by research laboratories throughout [i]Europe, China, Japan and North America, the value of our intellectual property ("IP") portfolio is steadily increasing. We are continually expanding our IP portfolio for MANF by filing and aggregating new patents.
While these developments are of significant importance for the Company, advancing MANF as a disease-modifying treatment for Parkinson's disease continues to be our primary focus. We anticipate announcing interim results from on-going delivery experiments by the end of October.